Cynomolgus monkeys had microdialysis probes implanted under ketamine anesthesia into peripheral veins, thigh muscles, and the brain in order to sample the extracellular fluid for the concentrations of unbound nucleoside analogs. A dose of 25 mg of zidovudine or 3'-fluoro-3'-deoxythymidine (FLT) per kg was administered subcutaneously to each of three animals. Relatively high antiviral concentrations of FLT Microdialysis. Anesthesia was induced by and maintained with ketamine given intravenously. The monkeys were placed in a stereotaxic instrument. In each monkey two microdialysis probes (CMA/10; CMA Microdialysis AB, Stockholm, Sweden) with a diffusible area of 10.0 by 0.5 mm (length by outer diameter) were implanted bilaterally into the striatum through a guide cannula which was secured to the skull bone by means of an acrylic dental cement. Two microdialysis probes were also implanted in muscle tissue in the thigh, and two probes were implanted into a dorsal superficial vein of the lower limb. Duplicate probes were used to prevent loss of data. Dialysates were collected in 20-min fractions and covered with tube caps. After implantation, each microdialysis probe was perfused for 60 min with degassed Ringer solution (ACO, Stockholm, Sweden) at a constant flow rate of 2.0 pl/min. Next, to determine the recovery over the dialysis membrane in vivo, each probe was perfused with a 10 ,uM solution of zidovudine or FLT at the same rate for 60 min and then the perfusion medium was switched back to Ringer solution for a washout period. The loss of drug to the tissue by diffusion over the dialysis membrane was measured as the difference between the drug concentration in the perfusion medium (10 ,uM) and the drug concentration in the dialysate. The proportion of drug lost over the dialysis membrane was used as an estimate of the in vivo recovery (18) . After the washout period of 60 min,
The search for new drugs against the human immunodeficiency virus (HIV) is intensive, as mirrored by the frequent appearance of review articles in this field (e.g., see references 4, 7, 15, and 17) . The preclinical models used in the development of new compounds primarily involve in vitro assays for HIV replication in combination with some tissue culture models to assess toxicity. Animal models of HIV infection have only recently become available, the clinically most relevant probably being infection of macaque monkeys with the simian immunodeficiency virus (SIV) (5, 13) or with HIV type 2 (HIV-2) (16) . The effects of zidovudine and 3'-fluoro-3'-deoxythymidine (FLT) on HIV-1 in vitro (9) and on SIV-infected monkeys in vivo (12) were recently investigated, and it was found that FLT is approximately 10 times more potent than zidovudine. The pharmacokinetic properties of FLT are similar to those of zidovudine in monkeys, the most important difference being that FLT is not protein bound (12) .
The distribution in various tissues of drugs against HIV is a factor of considerable importance. In particular, good distribution in the brain is desirable since a major clinical problem in the management of AIDS is the presence of neuropsychiatric symptoms (10) . Previous studies of zidovudine distribution have used measurement of cerebrospinal fluid (CSF) in humans (8) or the intracarotid/first pass extraction technique to study blood-brain barrier permeability (21) . In the present study we used the microdialysis method for measuring free (not protein-bound) extracellular tissue concentrations of drugs in the brain and other tissues (18) comparison between FLT and zidovudine with respect to AUC was made by Student's t test.
(ii) Antiviral effects of zidovudine and FIT. The antiviral effects of zidovudine (n = 4) and FLT (n = 4) in SIV-infected monkeys were assessed as the delay in appearance of p24 antigen compared with that in saline-treated controls (n = 8). Statistical significance was assessed by the Mann-Whitney U test with a = 0.05.
RESULTS
Kinetics and distribution of FIT. The time-concentration curves for FLT for each monkey are given in Fig. 2 . The variation between blood probes was smaller for FLT than for zidovudine ( Table 1 ). The maximum concentration of FLT appeared earlier than that of zidovudine in all tissues (Fig.  2) . For muscle the mean maximum concentration in the dialysate (Cmax) was 44.6 + 1.2 ,uM. The time to maximum concentration in the dialysate (Tmax) for extracellular concentrations in the brain varied from 70 to 130 min, with a Cmx, of 12.8 ± 3.5 ,uM, but was consistently found to be 50 min for muscle and veins. The brain/muscle AUCO-180 ratio was 0.30 ± 0.05.
Kinetics and distribution of zidovudine. The time-concentration curves for zidovudine for each monkey are given in Fig. 3 Delay of viral replication in SWV-infected monkeys. The serum antigen levels in SIV-infected monkeys treated with FLT, zidovudine, or vehicle are shown in Fig. 4 . Both zidovudine and FLT delayed the appearance of viral antigen, and the peak levels were lower than those for the controls. With the stated doses of drug and the infective dose of SIV, the antiviral treatments did not prevent viral replication, in spite of the fact that treatment started prior to infection. 
DISCUSSION
In the present study we showed that the extracellular concentrations of zidovudine and FLT in blood, muscle, and the brain in vivo are well within the concentration ranges at which antiviral effects can be observed both in vivo (12, 13) and in in vitro systems (1, 14 culture (0.005 to 0.1 ,uM) (1, 9, 14) . Furthermore, in the in vivo SIV model both drugs displayed a significant antiretrovirus efficacy (Fig. 4) .
The present study was in part undertaken to clarify the discrepancy observed in rat studies between those using microdialysis (20) and whole-tissue measurements (6, 21) and also the discrepancy between human (8) and rat (6) CSF (20) . Together, these data suggest that the extracellular concentration of zidovudine in the brain is highest in humans, intermediate in monkeys, and lowest in rats. The similarity ,. \ between the distribution of zidovudine and FLT in rats and monkeys suggests that the distribution of both drugs should also be similar in humans.
It remains to be discussed why whole-tissue data for rats I / . ,',\.
differ from extracellular data. Galinsky et al. (6) In the present study we found that extracellular concentrations of zidovudine in the brain are about one-third of unbound concentrations in plasma. Collins et al. (2) reported that levels in CSF in rhesus monkeys are about one-fifth of total levels in plasma which, when corrected for plasma protein binding (12) , closely agree with the present findings. Interestingly, it has been found that levels of zidovudine in CSF in humans are about 50% of total levels in plasma 4 h after administration (i.e., almost 100% of the free concentration in plasma) (8) . This figure is taken as an approximate average from a study (8) in which single measurements of zidovudine in CSF were taken after various modes of administration in a small number of patients. Hence, 50% is not a figure of considerable accuracy (as opposed to microdialysis data, in which the whole time-concentration curve is available for each tissue studied). In rats we found, by microdialysis, that the free extracellular concentration is
